Immunic (IMUX) Stock Forecast: StockMap's 2-Week Call
IMUX stock forecast: StockMap's model leans Underperform on Immunic for the two weeks after the Nov 18 close, toward IMUX trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 5 of 6 two-week windows on IMUX since Aug 21; by chance, a call on the same dates was right 60% of the time.
Immunic last closed at $7.52, +2.59% on the session.
Against the IVW growth benchmark the position is +2.57% over the forecast window.
Immunic's market cap is $119.42M as of November 18, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -36 (too close to call).
Where IMUX sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 3 bullish and 12 bearish.
Agreement across those insights is 80%.
48 daily calls for IMUX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Immunic in the 7th percentile on return on equity, where 100 is best.
Immunic is classified under Health Care / Biotechnology.
StockMap tracks Immunic as the 264th largest of the 393 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 195 Moderate Underperform, 141 Neutral, 42 Strong Underperform and 15 Moderate Outperform.
On that composite Immunic ranks 274th of 393 in the group, against a group median of -0.27.